Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
HeXun Biosciences Co's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 180.86.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. HeXun Biosciences Co's liquidation value for the
six
months ended in Jun. 2026 was NT$793.6 Mil.
HeXun Biosciences Co (ROCO:6986) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
HeXun Biosciences Co's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeXun Biosciences Co Change In Receivables Related Terms
HeXun Biosciences Co Change In Receivables Historical Data
* Premium members only.
The historical data trend for HeXun Biosciences Co's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeXun Biosciences Co Change In Receivables Calculation
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-20.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of NT$-20.6 Mil mean?
HeXun Biosciences Co (ROCO:6986) has a Change In Receivables of NT$-20.6 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for HeXun Biosciences Co and its competitors.
Is HeXun Biosciences Co's Change In Receivables too high?
HeXun Biosciences Co's current Change In Receivables is NT$-20.6 Mil. Overall, HeXun Biosciences Co has a GF Score™ of 42/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Change In Receivables compare to VRTX and REGN?
HeXun Biosciences Co's Change In Receivables of NT$-20.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for HeXun Biosciences Co and its competitors. HeXun Biosciences Co's current Change In Receivables is NT$-20.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, HeXun Biosciences Co (ROCO:6986) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$110.18, compared to a current price of NT$40.25 — trading 63.5% below its estimated fair value. The current Change In Receivables is NT$-20.6 Mil. HeXun Biosciences Co's overall GF Score™ is 42/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Change In Receivables is NT$-20.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HeXun Biosciences Co (ROCO:6986) Overvalued in 2026?
Based on GuruFocus' analysis, HeXun Biosciences Co stock appears to be undervalued.
The current stock price of NT$40.25 is trading 63.5% below its estimated GF Value™ of NT$110.18.
GuruFocus considers HeXun Biosciences Co to be Significantly Undervalued.
Key valuation signals for ROCO:6986:
Change In Receivables: NT$-20.6 Mil
GF Value™: NT$110.18 vs. price of NT$40.25 (63.5% below fair value)
No single metric tells the full story. See the ROCO:6986 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
42GF Score
Get the complete analysis for ROCO:6986
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6986 has been successfully added to your 
